EH&BRR is an extension of UTMB Environmental Health and Safety (EHS) and as such provides crifical health, safety, and training services;maintains consistency in biosafety and biocontainment pracfices; provides biosafety theory educafion and hands-on training in conjunction with the National Biocontainment Training Center. The Core implements all of the requirements for possession, use and storage of select agents and toxins stipulated by 42 CFR 73 National Select Agent Registration Program. EH&BRR staff continuously maintain and monitor the integrity of the BSL4 containment areas;provide expertise in areas of primary containment operations;lead decontamination, retesting, and support the maintenance and certification of BSL4 containment facilifies. The Core responds to potential emergency events and plans for the orderiy shutdown and decontamination of containment due to weather or other events. The primary objective for the Environmental Health and Biosafety Regulations and Requirements Core is to continue to ensure that the GNL is fully compliant with all select agent, safety and security regulations, and university requirements and that the facility is well prepared for all adverse weather or other events.

Public Health Relevance

The EH&BRR core provides essenfial support to meet local, state and federal regulations, including environmental health and safety aspects of biological, chemical and radiological protection, hazardous waste management, occupational health, and fire safety. The core coordinates research across institutional committees and provides training to individuals involved in high and maximum containment labs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
National Biocontainment Laboratory Operation Cooperative Agreement (UC7)
Project #
5UC7AI094660-02
Application #
8376440
Study Section
Special Emphasis Panel (ZAI1-PRJ-M)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
2
Fiscal Year
2012
Total Cost
$539,263
Indirect Cost
$166,232
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A et al. (2018) Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 49:363-374.e10
Cross, Robert W; Mire, Chad E; Agans, Krystle N et al. (2018) Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J Infect Dis 218:S448-S452
Gilchuk, Pavlo; Mire, Chad E; Geisbert, Joan B et al. (2018) Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. J Infect Dis 218:S565-S573
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest 127:4437-4448
Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149
Warfield, Kelly L; Warren, Travis K; Qiu, Xiangguo et al. (2017) Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo. Antiviral Res 138:22-31
Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6
Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430
Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates. J Infect Dis 214:S367-S374

Showing the most recent 10 out of 59 publications